Vmn1r94 Inhibitors
Vmn1r94, a vital member of the vomeronasal receptor family, plays a pivotal role in detecting pheromones and orchestrating social and reproductive behaviors across various species. Positioned within the vomeronasal organ, Vmn1r94 functions as a chemosensory receptor, responding to specific chemical cues and translating them into neuronal signals that drive species-specific behaviors. The inhibition of Vmn1r94 involves a complex interplay of molecular events influenced by various chemicals acting either directly or indirectly on the receptor.
Direct inhibitors, such as LY294002 and U0126, target specific signaling pathways like PI3K-Akt and MAPK, respectively, disrupting crucial elements for Vmn1r94 expression and function. Indirect inhibitors, including SB-431542 and LY411575, modulate broader pathways like TGF-β and Notch, impacting downstream targets related to Vmn1r94 activity. These inhibitors collectively highlight the intricate regulatory mechanisms governing Vmn1r94 and offer insights into potential strategies for modulating chemosensory responses. The exploration of chemical inhibitors enriches our understanding of Vmn1r94 inhibition, shedding light on the intricate connections between cellular pathways and the regulation of vomeronasal receptor function within the organ.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a specific PI3K inhibitor, directly targets the PI3K-Akt pathway, impacting Vmn1r94. This inhibition disrupts downstream signaling cascades crucial for Vmn1r94 expression and function, resulting in a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK1/2 inhibitor, directly impedes Vmn1r94 by disrupting the MAPK pathway. This interference alters downstream elements crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a potent PI3K inhibitor, directly hampers Vmn1r94 by disrupting the PI3K-Akt pathway. This interference alters downstream elements crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542, a selective TGF-β type I receptor inhibitor, indirectly inhibits Vmn1r94 expression by obstructing the TGF-β signaling pathway. This disruption influences downstream elements affecting gene transcription related to Vmn1r94 activity, resulting in a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059, a MEK inhibitor, directly impacts Vmn1r94 by disrupting the MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 202190, a p38 MAPK inhibitor, directly targets Vmn1r94 by disrupting the p38 MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2109761, a TGF-β receptor inhibitor, indirectly hampers Vmn1r94 expression by disrupting the TGF-β signaling pathway. This disruption influences downstream elements affecting gene transcription related to Vmn1r94 activity, resulting in a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $198.00 $473.00 | 6 | |
LY411575, a γ-secretase inhibitor, indirectly influences Vmn1r94 by disrupting the Notch signaling pathway. This interference alters downstream targets crucial for Vmn1r94 expression and function, resulting in a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly impedes Vmn1r94 by disrupting the JNK signaling pathway. This interference alters downstream elements crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715, a p38 MAPK inhibitor, directly impacts Vmn1r94 by disrupting the p38 MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r94 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||